WO2013051414A1 - ピロロキノリンキノンアルコール付加物 - Google Patents
ピロロキノリンキノンアルコール付加物 Download PDFInfo
- Publication number
- WO2013051414A1 WO2013051414A1 PCT/JP2012/074411 JP2012074411W WO2013051414A1 WO 2013051414 A1 WO2013051414 A1 WO 2013051414A1 JP 2012074411 W JP2012074411 W JP 2012074411W WO 2013051414 A1 WO2013051414 A1 WO 2013051414A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pqq
- salt
- alcohol
- adduct
- methanol
- Prior art date
Links
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 title claims description 511
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims description 209
- 150000003839 salts Chemical class 0.000 claims abstract description 76
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 10
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims abstract description 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 41
- 239000002904 solvent Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 33
- 235000013305 food Nutrition 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 15
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 14
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000007910 chewable tablet Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 3
- 239000008271 cosmetic emulsion Substances 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 3
- 239000003337 fertilizer Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 21
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract 2
- ZIUYHTQZEPDUCZ-UHFFFAOYSA-N 7h-pyrrolo[2,3-h]quinoline Chemical compound C1=CN=C2C(C=CN3)=C3C=CC2=C1 ZIUYHTQZEPDUCZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000001258 Cinchona calisaya Nutrition 0.000 abstract 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 1
- 229960000948 quinine Drugs 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 189
- 239000007787 solid Substances 0.000 description 35
- -1 alkali metal salt Chemical class 0.000 description 33
- 239000000047 product Substances 0.000 description 32
- 238000002211 ultraviolet spectrum Methods 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- 229910052783 alkali metal Inorganic materials 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 150000002373 hemiacetals Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 3
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 3
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 244000294411 Mirabilis expansa Species 0.000 description 3
- 235000015429 Mirabilis expansa Nutrition 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- UFVBOGYDCJNLPM-UHFFFAOYSA-L disodium;9-carboxy-4,5-dioxo-1h-pyrrolo[2,3-f]quinoline-2,7-dicarboxylate Chemical compound [Na+].[Na+].C12=C(C([O-])=O)C=C(C([O-])=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 UFVBOGYDCJNLPM-UHFFFAOYSA-L 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000013536 miso Nutrition 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 0 *OC1(c2nc(C(O)=O)cc(C(O)=O)c2-c([n]c(C(O)=O)c2)c2C1=O)O Chemical compound *OC1(c2nc(C(O)=O)cc(C(O)=O)c2-c([n]c(C(O)=O)c2)c2C1=O)O 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000010413 gardening Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003333 secondary alcohols Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- QWOZZTWBWQMEPD-UHFFFAOYSA-N 1-(2-ethoxypropoxy)propan-2-ol Chemical compound CCOC(C)COCC(C)O QWOZZTWBWQMEPD-UHFFFAOYSA-N 0.000 description 1
- RWNUSVWFHDHRCJ-UHFFFAOYSA-N 1-butoxypropan-2-ol Chemical compound CCCCOCC(C)O RWNUSVWFHDHRCJ-UHFFFAOYSA-N 0.000 description 1
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- QCAHUFWKIQLBNB-UHFFFAOYSA-N 3-(3-methoxypropoxy)propan-1-ol Chemical compound COCCCOCCCO QCAHUFWKIQLBNB-UHFFFAOYSA-N 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- PSJQCAMBOYBQEU-UHFFFAOYSA-N Glyoxalase I Natural products CC=CC(=O)OCC1=CC(O)C(O)C(O)C1=O PSJQCAMBOYBQEU-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014017 Lactoylglutathione lyase Human genes 0.000 description 1
- 108010050765 Lactoylglutathione lyase Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001437 anti-cataract Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- QMNOIORHZMRPLS-UHFFFAOYSA-N butan-1-ol;ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CCCCO.CC(O)CO QMNOIORHZMRPLS-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000014537 nerve growth factor production Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000008519 pasta sauces Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/58—Colouring agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/40—Colouring or decolouring of foods
- A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
- A23L5/47—Addition of dyes or pigments, e.g. in combination with optical brighteners using synthetic organic dyes or pigments not covered by groups A23L5/43 - A23L5/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
- A61Q1/06—Lipsticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
Definitions
- the present invention relates to a novel derivative of pyrroloquinoline quinone represented by the following formula (1).
- PQQ Pyrroloquinoline quinone
- PQQ Pyrroloquinoline quinone
- PQQ has been proposed as a new vitamin, and has attracted attention as a useful substance in health supplements, cosmetics and the like.
- PQQ is present not only in bacteria but also in eukaryotic fungi and yeast, and plays an important role as a coenzyme.
- PQQ has many cell proliferation promoting effects, anti-cataract effects, liver disease preventive and therapeutic effects, wound healing effects, anti-allergic effects, reverse transcriptase inhibitory effects and glyoxalase I inhibitory effects-anticancer effects, etc. It has been clarified to have the physiological activity.
- PQQ has absorption in the visible part. Therefore, the free form and alkali metal salt of PQQ are solids or solutions of red to dark red (see, for example, Non-Patent Documents 1, 2, and 3).
- a derivative of PQQ for example, a derivative obtained by esterifying a carboxylic acid in PQQ with an alcohol has been reported (for example, see Non-Patent Documents 2 and 4).
- Patent Document 1 a composition containing PQQ and alcohol has been reported so far (see, for example, Patent Document 1).
- a reaction product of PQQ and alcohol a carboxylic acid ester of PQQ and a hemiacetal body to which an alcohol has been added have been reported (for example, see Non-Patent Document 5).
- PQQ has many physiological activities as described above, and therefore it has been studied to contain it in foods and cosmetics.
- the free form of PQQ and the alkali metal salt described in Patent Documents 1 to 3 are red to dark red, so that if they are contained as they are in foods and cosmetics, the palatability may be lowered. Therefore, the free form of PQQ and its salts (for example, alkali metal salts), when included in foods and cosmetics, maintain a function of PQQ and take into consideration the high palatability of foods and cosmetics, It is required to change the color.
- a method of changing the color of the free form of PQQ and its salt a method of changing the chemical structure can also be mentioned.
- the esterified PQQ derivatives described in Non-Patent Documents 2 and 4 are considered to change the absorption wavelength (color) because the chemical structure changes from the original PQQ.
- Such esterified derivatives of PQQ are considered to be hydrolyzed relatively easily and return to the original PQQ, but the hydrolysis rate is actually slow and it is difficult to return to the original PQQ.
- the carboxylic acid ester of PQQ and its hemiacetal form described in Non-Patent Document 5 are unlikely to return to the original PQQ. Therefore, although the method of changing the chemical structure can change the color, the change in physical properties is large, and it is difficult to obtain the original PQQ function.
- composition containing PQQ and alcohol described in Patent Document 1 is merely a composition, not a reaction product of PQQ and alcohol.
- an object of the present invention is to provide a novel compound that can improve the red color of PQQ and obtain the function of the original PQQ, and to provide an efficient production method of the compound.
- [1] A compound represented by the following formula (A) or (B) or a salt thereof.
- R is an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group or an alkoxyalkyl group.
- [2] The composition containing the compound or its salt as described in [1].
- [3] The composition according to [2], further comprising coenzyme Q10.
- [4] A beverage using the compound according to [1] or a salt thereof, or the composition according to [2] or [3].
- [5] A food using the compound according to [1] or a salt thereof, or the composition according to [2] or [3].
- R is an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group or an alkoxyalkyl group.
- FIG. 4 is a diagram illustrating a UV spectrum result of the product obtained in Comparative Example 1. It is a figure showing the UV spectrum result of the product obtained in Reference Example 1. It is a figure showing the UV spectrum result of the product obtained in Example 8-1. It is a figure showing the UV spectrum result of the product obtained in Example 8-2. It is a figure showing the UV spectrum result of the product obtained in Example 8-3. It is a figure showing the UV spectrum result of the 100% methanol solution obtained in Example 26-1.
- Example 27-3 It is a figure showing the UV spectrum result of the 5% methanol solution obtained in Example 26-2. It is a figure showing the UV spectrum result of the product obtained in Comparative Example 7. It is a figure showing the UV spectrum result of the product obtained in Reference Example 4. It is a figure showing the UV spectrum result of the product obtained in Example 27-1. It is a figure showing the UV spectrum result of the product obtained in Example 27-2. It is a figure showing the UV spectrum result of the product obtained in Example 27-3.
- the present embodiment is a compound represented by the following formula (A) or (B) or a salt thereof.
- R is an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group or an alkoxyalkyl group.
- R is preferably a methyl group, an ethyl group, a propyl group, a hydroxyethyl group, a hydroxypropyl group or a dihydroxypropyl group, more preferably an ethyl group, a methyl group or a propyl group.
- the compound of the present embodiment or a salt thereof is, for example, a pyrroloquinoline quinone represented by the following formula (1) (hereinafter sometimes referred to as “PQQ” or “PQQ free form”) or a salt thereof, It can be obtained by adding 1 equivalent of the alcohol represented by (2) (hereinafter sometimes referred to as “alcohol”).
- R is an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group or an alkoxyalkyl group.
- the salt of PQQ represented by the above formula (1) is not particularly limited, and examples thereof include mono-, di- or trialkali metal salts of PQQ and mono-, di- or triammonium salts of PQQ. More specifically, PQQ monosodium salt, PQQ disodium salt, PQQ trisodium salt, PQQ monopotassium salt, PQQ dipotassium salt, PQQ tripotassium salt, PQQ monolithium salt, PQQ dilithium salt Salt, trilithium salt of PQQ, monoammonium salt of PQQ, diammonium salt of PQQ, and triammonium salt of PQQ.
- the PQQ or a salt thereof used in the present embodiment is preferably a free form of PQQ, a monoalkali metal salt of PQQ or a monoammonium salt of PQQ, and particularly preferably an easily available free form of PQQ or PQQ.
- R is preferably an alkyl group having 1 to 700 carbon atoms, a hydroxyalkyl group, a dihydroxyalkyl group or an alkoxyalkyl group.
- the primary amino group is not included.
- the molecular weight of the alcohol represented by the above formula (2) is preferably 30 to 10,000, more preferably 32 to 1,000.
- the reactivity with respect to PQQ represented by the formula (1) or a salt thereof tends to be good.
- a primary or secondary alcohol is preferable.
- the primary or secondary alcohol has little steric hindrance, and can be rapidly added to the PQQ represented by the above formula (1) or a salt thereof.
- PQQ added with the alcohol easily dissociates the alcohol added in water. Function is easy to obtain.
- alcohol represented by the above formula (2) are not particularly limited.
- the alcohol represented by the above formula (2) is preferably methanol, ethanol, propanol, propylene glycol, ethylene glycol, or glycerin, more preferably methanol, propanol, ethanol, propylene glycol, or glycerin, and still more preferably. Ethanol.
- the compound represented by the following formula (A) or (B) or a salt thereof has, for example, 1 of the alcohol of the above formula (2) relative to PQQ represented by the above formula (1) or a salt thereof.
- An equivalent amount of a compound or a salt thereof hereinafter also referred to as “PQQ alcohol adduct”.
- R is an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group or an alkoxyalkyl group.
- the PQQ alcohol adduct of this embodiment has an advantage that the physical properties of PQQ can be changed without requiring a special reagent or catalyst.
- the solid or liquid of the original PQQ is red, but when the alcohol is added to PQQ, the PQQ alcohol adduct becomes a light yellow to yellow solid or liquid. Since the conjugated system in PQQ is cut by adding alcohol to PQQ, the PQQ alcohol adduct of this embodiment appears to the human eye as a yellowish color. For this reason, the PQQ alcohol adduct of this embodiment is easy to use for applications in foods and cosmetics that have particularly high palatability when a color other than red is desired.
- the PQQ alcohol adduct of this embodiment is similar to the color of coenzyme Q10 when mixed with coenzyme Q10, so that the color is not easily mottled.
- the PQQ alcohol adduct of this embodiment is easily dissociated in alcohol and returns to the original PQQ in water, the same function as PQQ can be obtained when administered orally.
- the PQQ alcohol adduct of this embodiment tends to return to the original PQQ by dissociating the added alcohol in an aqueous solution containing 80% by mass or more of water.
- the PQQ alcohol adduct of this embodiment is preferable because the alcohol is easily dissociated when the added alcohol is primary.
- the function of alcohol cannot be described as a function of any alcohol, but in the case of low molecular weight ethanol or methanol, it has a bactericidal property, thus reducing the risk of substances being contaminated with bacteria. Etc.
- the PQQ alcohol adduct of this embodiment can reduce the dissociation property of alcohol by using, for example, an alcohol having a large steric hindrance as an alcohol to be added, solubility in a solvent, and absorption into a cell. Etc. can be changed.
- the manufacturing method of the PQQ alcohol adduct of this embodiment includes the process of adding 1 equivalent of alcohol represented by following formula (2) to PQQ represented by following formula (1) or its salt.
- R is an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group or an alkoxyalkyl group.
- the PQQ free form or a salt thereof may be a solid, or may be dissolved in a solvent to form a solution.
- the PQQ-free body it is possible to use the PQQ-free body as it is, but it is also possible to use a PQQ-free body generated by acidifying the salt of PQQ in the solution.
- a free form is generated from a salt of PQQ
- the pH in the solution varies depending on the solvent and salt to be mixed, but in the case of a general aqueous solution, it is preferably 2 or less.
- the generated PQQ-free material can be dried and used separately.
- the salt of PQQ used in the production method of the present embodiment is not particularly limited, and examples thereof include mono-, di- or trialkali metal salts of PQQ and mono-, di- or triammonium salts of PQQ. More specifically, PQQ monosodium salt, PQQ disodium salt, PQQ trisodium salt, PQQ monopotassium salt, PQQ dipotassium salt, PQQ tripotassium salt, PQQ monolithium salt, PQQ dilithium salt Salt, trilithium salt of PQQ, monoammonium salt of PQQ, diammonium salt of PQQ, and triammonium salt of PQQ. Preferred is a dialkali metal salt of PQQ, and more preferred is a disodium salt of PQQ or a dipotassium salt of PQQ.
- PQQ di- or tri-alkali metal salt or PQQ di- or tri-ammonium salt is preferably used as a free form of PQQ, a mono-alkali metal salt of PQQ, or a mono-ammonium salt of PQQ by treatment with an acid.
- the salt of PQQ is preferably a monoalkali metal salt.
- an alkali metal salt of PQQ as a salt of PQQ
- an acid that becomes a salt with an alkali metal such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, citric acid, tartaric acid, acetic acid, etc. is added to remove moisture, etc.
- an acid that becomes a salt with an alkali metal such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, citric acid, tartaric acid, acetic acid, etc.
- the same alcohol as that added to PQQ may be used as the solvent. That is, the alcohol to be added is preferably used as a solvent.
- the solvent is preferably a solvent that does not react with PQQ, and includes, for example, an aprotic polar solvent. Aprotic polar solvents have good solubility in PQQ and are easy to use.
- the amount of the solvent used is preferably in the range of 0.5 mL to 1000 L with respect to 1 g of PQQ.
- the step is preferably performed in a solvent having a water content of 50% by mass or less.
- the amount of water in the solvent is more preferably 20% by mass or less, and still more preferably 10% by mass or less.
- the amount of water in the solvent is within the above range, the discoloration of PQQ tends to proceed favorably, and the formed hemiacetal structure is difficult to break and it is difficult to return to the original PQQ structure. Note that, in a situation where there is a lot of water, such as in a living body, the PQQ alcohol adduct returns to the original PQQ free body and exhibits the same function as the PQQ free body.
- a PQQ free body or its salt it is preferable to contact a PQQ free body or its salt, and alcohol at 0 to 200 degreeC.
- a PQQ free body or its salt can be efficiently changed in color from red to yellow.
- the contact temperature between the PQQ-free product or a salt thereof and the alcohol is more preferably 20 ° C. to 150 ° C., and further preferably 30 ° C. to 120 ° C.
- the contact time between the PQQ-free body or a salt thereof and the alcohol varies depending on conditions such as temperature and alcohol used, but may be, for example, about 30 seconds to 1 week.
- the PQQ alcohol adduct can be produced in several minutes even at room temperature due to the high reactivity of methanol or ethanol. That is, a PQQ alcohol adduct is formed at the same time as the PQQ free form or a salt thereof is diluted and mixed with alcohol as a solvent.
- the alcohol is preferably brought into contact with the PQQ-free body or a salt thereof in a liquid or gas state, and more preferably brought into contact with the PQQ-free body or a salt thereof in a liquid state.
- the blending ratio (molar ratio) of the PQQ-free body or a salt thereof and the alcohol only needs to be excessive.
- the blending ratio (PQQ free body or salt thereof: alcohol) is more preferably 1:10 to 100,000. By setting it as such a mixture ratio, 1 equivalent of alcohol can be added to PQQ or its salt.
- the PQQ alcohol adduct formed by contacting the PQQ free form or a salt thereof with an alcohol may be isolated, or can be used for various applications described later even in the state of coexisting with unreacted alcohol. .
- a method for isolating the PQQ alcohol adduct when the PQQ alcohol adduct is precipitated as a solid, a method of recrystallization using a solvent can be mentioned. If the PQQ alcohol adduct is stable, a separation method such as chromatography can also be used.
- a specific method for producing the PQQ alcohol adduct of the present embodiment will be described.
- a method for producing a PQQ ethanol adduct will be described.
- PQQ disodium salt is dissolved in water to obtain an aqueous solution.
- hydrochloric acid is added to the aqueous solution to adjust the pH to 0 to 2
- a red solid is precipitated.
- the precipitated red solid is collected by filtration, washed with 2N or less hydrochloric acid, washed with water and isopropanol, and then dried under reduced pressure to obtain a PQQ free body.
- the obtained PQQ free body is added to ethanol to the PQQ free body by heating in an ethanol solvent below the boiling point of ethanol. When heating above the boiling point of ethanol, it is preferably carried out in a pressure vessel. As the addition reaction proceeds, the solution turns from red to yellow, and a yellow solid precipitates. The precipitated yellow solid is isolated by centrifugation or filtration. A light yellow solid can be obtained by air-drying or vacuum drying the isolated yellow solid. This pale yellow solid is the PQQ ethanol adduct.
- the method for storing the PQQ alcohol adduct of the present embodiment is not particularly limited, and examples thereof include a storage method such as low-temperature storage, anaerobic storage using a sealed container, and shading storage. Further, the PQQ alcohol adduct of this embodiment may be dissolved in a solvent to form a solution and stored by the above method. According to the method described above, the PQQ alcohol adduct can be stably stored without deposits.
- composition of this embodiment contains the above-mentioned PQQ alcohol adduct.
- the PQQ alcohol adduct may be used alone or in combination of two or more.
- composition of the present embodiment may further contain the original PQQ, coenzyme Q10, vitamins such as ascorbic acid, and other food ingredients, and preferably further contains coenzyme Q10.
- Coenzyme Q10 may be either reduced or oxidized coenzyme Q10, with oxidized coenzyme Q10 being preferred.
- composition of the present embodiment is a powder, tablet, chewable tablet, capsule, granule, injection, liquid, eye drop, lotion, hair tonic, cosmetic emulsion, spray liquid, aerosol, drink liquid, liquid fertilizer or It is preferably in the form of a storage solution.
- PQQ may be used alone as a food to be contacted with alcohol to be converted into a PQQ alcohol adduct and discolored.
- PQQ is mixed with other food and then contacted with alcohol to form PQQ alcohol. It may be converted into an adduct and discolored.
- the composition of the present embodiment may be in the form of powder or solution.
- the mixing with the other components may be performed in a powder state, and the solvent is removed by mixing in a solution state. It may be solid, and any method may be adopted even if the component in the powder state and the component in the solution state are mixed.
- the compound of the present embodiment or a salt thereof, or the composition of the present embodiment is, for example, a pharmaceutical, a quasi-drug, a cosmetic, a beverage, a food (beverage and food are collectively referred to as “food and beverage”), and a function.
- a pharmaceutical, a quasi-drug, a cosmetic, a beverage, a food beverage and food are collectively referred to as “food and beverage”
- food and beverage a function.
- the food or drink, the functional food and the feed using the compound of the present embodiment or a salt thereof, or the composition of the present embodiment are effective based on the physiological action of PQQ, such as cell proliferation promotion, liver disease prevention treatment, melanin production It exhibits effects such as suppression and nerve growth factor production promotion. Therefore, as a beverage, food, functional food, and feed using the compound of the present embodiment or a salt thereof, or the composition of the present embodiment, the health food and the function indicating that effect are intended. Suitable for sex foods, foods for specified health use, foods and drinks for the sick, feed for livestock, racehorses or appreciation animals, pet foods and the like.
- Food / beverage products, functional foods, feeds and horticultural products using the compound of the present embodiment or a salt thereof, or the composition of the present embodiment are other products used for the production of food / beverage products, functional foods, feeds and horticultural products.
- Materials such as various nutrients, various vitamins, minerals, amino acids, various fats and oils, various additives (for example, flavoring ingredients, sweeteners, sour agents such as organic acids, preservatives, thickening stabilizers, color formers, bleaching Agents, antibacterial / antifungal agents, surfactants, pH adjusters, stabilizers, antioxidants, pigments, flavors, etc.) and the like, and can be produced according to conventional methods.
- the functional food, food and drink, feed and garden supplies of the present embodiment are produced by blending the composition of the present embodiment with food and drink, functional food, feed and garden supplies that are usually eaten. Can do.
- the form of the food / beverage product, functional food, feed, or gardening product is not particularly limited, and may be, for example, powder, solid, semi-solid or liquid, or may be a tablet, chewable tablet, powder, capsule, granule, drink, gel , Syrup, various forms such as liquid food for tube enteral nutrition.
- the form of the specific food and drink is not particularly limited.
- tea drinks such as green tea, oolong tea and tea, coffee drinks, soft drinks, jelly drinks, sports drinks, milk drinks, carbonated drinks, fruit juice drinks, lactic acid bacteria drinks , Fermented milk drinks, powdered drinks, cocoa drinks, alcoholic drinks, beverages such as purified water, miso, soy sauce, instant miso soup, ramen, yakisoba, curry, corn soup, merbo dofu, marvo eggplant, pasta sauce, pudding, cake, butter , Jams, sprinkles, margarine spreads, mayonnaise, shortening, custard cream, dressings, breads, cooked rice, noodles, pasta, miso soup, tofu, milk, yogurt, soup or sauces, confectionery (eg biscuits and cookies Kind, chocolate, candy, cake, ice cream, Yuingamu, tablet), and the like.
- the feed of this embodiment can be used in the same composition and form as food and drink and functional food.
- the medicine or quasi-drug may contain a pharmaceutically acceptable carrier.
- the carrier is not particularly limited, and examples thereof include excipients, coating agents, binders, extenders, disintegrating agents, lubricants, diluents, surfactants, osmotic pressure adjusting agents, pH adjusting agents, and dispersing agents. , Emulsifiers, preservatives, stabilizers, antioxidants, wetting agents, thickeners, injections, alcohol, water, water-soluble polymers, or coloring agents to add color, fragrance or flavor to flavors, flavorings, flavoring Agents, flavoring agents and the like. These carriers can be appropriately used alone or in any combination depending on the pharmaceutical or quasi-drug formulation.
- the dosage form for use in medicine or quasi-drug is preferably a dosage form for oral or transdermal administration.
- the dosage form of the oral preparation is not particularly limited, and examples thereof include tablets, capsules, granules, powders, syrups, dry syrups, liquids, suspensions and the like.
- Examples of the dosage form of the transdermal preparation are not particularly limited, and examples thereof include lotion, gel, cream, spray, ointment, patch, and patch.
- additives such as excipients, binders, disintegrants, lubricants, dispersants, suspending agents, emulsifiers, diluents, buffers, antioxidants, antibacterial agents, etc. Can be used.
- the dosage form for use in cosmetics is not particularly limited as long as it is usually used in cosmetics, for example, ointments, creams, emulsions, lotions, powders, packs, bathing agents, shampoos, rinses, treatments, lipsticks, Eyeliner, spray liquid, hair tonic and the like. Except for blending the composition of the present embodiment, it can be produced by the same method as that for ordinary cosmetics.
- UV measurement UV measurement of PQQ alcohol adducts and the like was performed using a U-2000 spectrometer manufactured by HITACHI.
- High performance liquid chromatography analysis of PQQ alcohol adducts and the like was performed as follows. Shimadzu high performance liquid chromatography LC-20A column: YMC-Pack ODS-TMS (5 ⁇ m) 150 ⁇ 4.6 mm D. And the eluent was detected at 260 nm using an absorbance detector with 100 mM CH 3 COOH / 100 mM CH 3 COONH 4 (30/70, pH 5.1).
- NMR Nuclear magnetic resonance
- FT-IR measurement FT-IR measurement of PQQ alcohol adducts and the like was performed with ATR (Dia) using Thermo Scientific NICOLET6700.
- Example 1 Methanol adduct 37 wt% concentrated hydrochloric acid was added to a 3 g / L aqueous solution of PQQ disodium, and the pH of the aqueous solution was adjusted to 2 or less to precipitate a red PQQ free form.
- the precipitated PQQ free body was collected by filtration and dried under reduced pressure to obtain PQQ free body powder.
- 0.25 g of the obtained PQQ-free powder was mixed with 40 g of methanol and reacted at 65 ° C. for 5 hours.
- the reaction solution was placed in an eggplant flask and the solvent was removed by an evaporator to obtain 0.28 g of a yellow solid slightly mixed with a red solid.
- the obtained solid was further washed with 6 mL of methanol to obtain 0.28 g of a pale yellow solid (PQQ methanol adduct).
- Example 2 Reaction with Methanol 1.5 g of the PQQ free body obtained in the same manner as in Example 1 was mixed with 39 g of methanol and placed in a glass bottle. When the glass bottle was placed in an ultrasonic cleaning apparatus and subjected to ultrasonic waves for 1 hour, the mixture in the bottle changed from red to yellow. The yellow mixture was separated with a centrifuge to give 3.48 g of solid. The obtained solid was left to dry in the air to obtain 1.40 g of a pale yellow solid (PQQ methanol adduct).
- Example 3 Reaction with Gaseous Methanol 30 mg of the PQQ-free product obtained in the same manner as in Example 1 was brought into contact with 8.5 g of methanol vapor at 66 ° C. for 30 minutes to convert the red solid PQQ-free product into a yellow solid. Was changed. 33 mg of the yellow solid (PQQ methanol adduct) was obtained. From this, it was found that even when gaseous alcohol was used, the reaction between the PQQ free body and the alcohol proceeded.
- Example 4 LC analysis
- the PQQ methanol adduct obtained in Example 1 was added to a phosphate buffer (Invitrogen pH 7.4) to obtain a 1 mg / ML PQQ methanol adduct solution.
- the PQQ methanol adduct solution was allowed to stand at room temperature for 2 hours and then analyzed by high performance liquid chromatography. The analysis revealed that PQQ was present at 0.92 mg / ML in the PQQ methanol adduct solution. That is, the PQQ methanol adduct obtained in Example 1 was returned to the original PQQ free form by adding a phosphate buffer and allowing it to stand at room temperature for 2 hours.
- Example 5 Ethanol adduct 1.98 g of the PQQ-free product obtained in the same manner as in Example 1 was mixed with 40 g of ethanol and reacted at 65 ° C. for 6 hours to precipitate a yellow solid. The precipitated yellow solid was centrifuged, washed with ethanol, and dried under reduced pressure to isolate 1.95 g of a pale yellow solid (PQQ ethanol adduct).
- Example 6 Methoxyethanol adduct 380 mg of the PQQ free product obtained in the same manner as in Example 1 was mixed with 15 g of methoxyethanol, reacted at 60 ° C. for 16 hours, and allowed to stand at room temperature for 3 days to precipitate a yellow solid. did. The precipitated yellow solid was centrifuged, washed with diethyl ether, and then dried under reduced pressure to isolate 0.28 g of a yellow solid (PQQ methoxyethanol adduct).
- Example 7 NMR, IR analysis The PQQ methanol adduct and PQQ ethanol adduct obtained in Examples 2 and 5 were analyzed as follows.
- Example 2 1) Measurement in deuterated methanol (CD 3 OD) solvent
- the PQQ methanol adduct obtained in Example 2 was subjected to two-dimensional measurement of 1 H-NMR, 13 C-NMR, HMBC and HMQC in deuterated methanol.
- NOESY measurement was performed to determine the structure of the PQQ ethanol adduct obtained in Example 5.
- the peaks of 7.31 s (1) and 8.76 s (1) ppm on the aromatic ring and the 1.17t (3) and 3.60q (2) ppm ethyl groups on the aromatic ring in 1 H-NMR in the above heavy methanol were obtained. There was no correlation with the peak.
- the portion derived from the PQQ structure had the same chemical shift as the peak of the PQQ free body in both 1 H-NMR and 13 C-NMR.
- the PQQ methanol adduct obtained in Example 2 showed a peak at 3.15 ppm in 1 H-NMR, in addition to the same chemical shift as the peak of the PQQ free form. The peak coincided with the chemical shift of methanol. In 13 C-NMR, a peak derived from a methyl group was observed at 48.66 ppm.
- the portion derived from the PQQ structure was the same chemical shift as the peak of the PQQ free body in both 1 H-NMR and 13 C-NMR.
- the peaks derived from the ethyl group showed 1.04t, 3.43 (q) in 1 H-NMR, and 18.62 and 56.06 in 13C.
- the PQQ methanol adduct obtained in Example 2 was subjected to 1 H- 1 HCOSY and NOESY measurements in heavy DMSO. Similar to the measurement in deuterated methanol, no correlation with other peaks was observed.
- the IR result of the PQQ methanol adduct obtained in Example 2 was almost the same as the IR result of the PQQ ethanol adduct obtained in Example 5. Peak of 3538cm -1 in the IR analysis of the PQQ-free body, the IR analysis of the obtained PQQ methanol adduct in Example 2 were changed and the peak of 3260cm -1, a peak of 3341cm -1 .
- Comparative Example 1 100% water Reference example 1: 90% by mass of water + 10% by mass of methanol
- Example 8-1 40% by mass of water + 60% by mass of methanol
- Example 8-2 10% by mass of water + 90% by mass of methanol
- Example 8-3 100% by mass of methanol
- the cultured Escherichia coli JM109 strain was diluted with a phosphate buffer (PBS) pH 7.4 manufactured by GIBCO to obtain a solution 1 having a turbidity of 0.57 at 660 nm.
- 100 ⁇ L of the solution 1 was added to 8 mg of each sample shown in Table 2, and after 30 minutes at room temperature, 900 ⁇ L of PBS was further added to obtain a solution 2.
- the solution 2 was planted in a petri dish of an LB agar medium and cultured at 30 ° C., whereby the number of viable bacteria was determined from the number of colonies in the solution 2.
- the PQQ alcohol adduct of this embodiment has an effect of suppressing the growth of bacteria and has a low risk of bacterial contamination while having the same function as PQQ.
- Examples 20 to 22 and Reference Examples 2 and 3 Reaction of PQQ disodium, hydrochloric acid, and ethanol As shown in Table 3, after adding a predetermined amount of 2N hydrochloric acid to 1 mL of a PQQ disodium aqueous solution 0.2M, and drying on a hot plate The reaction was allowed to react with 10 mL of ethanol at 50 ° C. for 1 hour, and the color change was observed.
- Example 25 2-Propanol Adduct 0.86 g of PQQ free product was mixed with 80 g of 2-propanol and reacted for 24 hours while heating under reflux. Isopropanol was removed from the obtained reaction solution with an evaporator to obtain 1.06 g of a yellow solid (PQQ2-propanol adduct).
- Example 26-1 PQQ disodium 10 mg of PQQ disodium was added to 10 mL of methanol to form a suspension. A solution (100% methanol solution) was prepared by diluting this suspension 20 times with methanol. The UV spectrum of the solution was measured. The results are shown in FIG.
- Example 26-2 PQQ disodium 10 mg of PQQ disodium was added to 10 mL of methanol to form a suspension. A solution (5% methanol solution) was prepared by diluting this suspension 20 times with water. The UV spectrum of the solution was measured. The results are shown in FIG.
- Example 26-1 and Example 26-2 In the UV spectra of Example 26-1 and Example 26-2, the 100% methanol solution has peaks at 250, 320 and 350 nm, and the 5% methanol solution has peaks at 250, 280 (shoulder) and 330 nm. there were. From these results, it was found that the shoulder disappeared in the 100% methanol solution. That is, even when PQQ disodium was used as a raw material, it showed the same reactivity as the PQQ free form, and it was found that a PQQ methanol adduct was produced.
- UV spectrum 10 mg of PQQ free material was added to 10 mL of each of the following solvents to obtain products. Further, the product was diluted 100 times with the following predetermined solvent, and the UV spectrum was measured.
- Comparative Example 7 100% by mass of water Reference Example 4: 90% by mass of water + 10% by mass of ethanol
- Example 27-1 40% by mass of water + 60% by mass of ethanol
- Example 27-2 10% by mass of water + 90% by mass of ethanol
- Example 27-3 100% by mass of ethanol
- Examples 28-1 to 28-8 Stability test As shown in Table 5, 5 mg of each sample was placed in a 0.25 mL polypropylene container and placed in an oven to change the temperature at 0.5, 3 and 24 hours, and Observed after 7 days. As the edible oil and fat, 100 ⁇ L of Nissin Oilio ODO was used.
- the PQQ alcohol adduct did not change color even when the container was opened at a high temperature when mixed with edible oils and fats. From this result, it was found that the edible fats and oils are effective for stabilizing the PQQ alcohol adduct of this embodiment.
- the present invention can be widely used as pharmaceuticals or quasi drugs, foods, functional foods, and feeds for humans or animals.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
下記式(A)又は(B)で表される化合物又はその塩。
〔2〕
〔1〕に記載の化合物又はその塩を含む組成物。
〔3〕
コエンザイムQ10をさらに含む〔2〕に記載の組成物。
〔4〕
〔1〕に記載の化合物若しくはその塩、又は〔2〕若しくは〔3〕に記載の組成物を用いた飲料。
〔5〕
〔1〕に記載の化合物若しくはその塩、又は〔2〕若しくは〔3〕に記載の組成物を用いた食品。
〔6〕
〔1〕に記載の化合物若しくはその塩、又は〔2〕若しくは〔3〕に記載の組成物を用いた化粧品。
〔7〕
粉末、錠剤、チュアブル錠、カプセル、顆粒、注射剤、液剤、点眼剤、ローション剤、ヘヤートニック、化粧用乳液、スプレー液、エアロゾル、ドリンク液、液体肥料又は保存用溶液の形態である〔2〕又は〔3〕に記載の組成物。
〔8〕
〔1〕に記載の化合物又はその塩を製造する方法であって、
下記式(1)で表されるピロロキノリンキノン又はその塩に、下記式(2)で表されるアルコールを1等量付加する工程を含む製造方法。
〔9〕
前記工程が水分量50質量%以下の溶媒中で行われる〔8〕に記載の製造方法。
〔10〕
前記ピロロキノリンキノンの塩がモノアルカリ金属塩である〔8〕又は〔9〕に記載の製造方法。
PQQフリー体又はその塩とアルコールとの接触温度が前記範囲内であると、PQQの変色が良好に進み、PQQの変質も抑制することができる。
PQQジナトリウムは三菱ガス化学製を使用した。特に明記のない試薬は、和光製を使用した。
(UV測定)
PQQアルコール付加物等のUV測定は、HITACHI製 U-2000 spectrometerを使用して行った。
PQQアルコール付加物等の高速液体クロマトグラフィー分析を以下のとおり行った。
島津製作所製高速液体クロマトグラフィーLC-20Aにカラム:YMC-Pack ODS-TMS(5μm) 150×4.6mm I.D.を設置し、溶離液を100mM CH3COOH/100mM CH3COONH4 (30/70, pH5.1)で吸光検出器を使用し260nmで検出した。
PQQアルコール付加物等の核磁気共鳴(NMR)測定を、JEOL製500MHz NMR、JNM-ECA500スペクトルメーターを使用して行った。
PQQアルコール付加物等のFT-IR測定を、Thermo Scienfitic NICOLET6700を使用しATR(Dia)で行った。
3g/LのPQQジナトリウム水溶液に37重量%の濃塩酸を加え、該水溶液のpHを2以下にして赤色のPQQフリー体を析出させた。析出したPQQフリー体を、ろ過により採取し、減圧乾燥することでPQQフリー体粉末を得た。得られたPQQフリー体粉末0.25gをメタノール40gと混合し、65℃で5時間反応させた。該反応液をナスフラスコに入れてエバポレーターで溶媒を除去することにより、赤い固体が少し混じった黄色の固体0.28gを得た。得られた固体をさらにメタノール6mLで洗うことで淡黄色い固体(PQQメタノール付加物)0.28gを得た。
実施例1と同様にして得られたPQQフリー体1.5gをメタノール39gと混合し、ガラス製ボトルに入れた。該ガラス製ボトルを超音波洗浄装置に入れ、1時間超音波にかけると、該ボトル中の混合物が赤色から黄色へと変化した。該黄色の混合物を遠心分離器で分離すると固体3.48gを得た。得られた固体を大気中で放置して乾燥し、淡黄色固体(PQQメタノール付加物)1.40g得た。
実施例1と同様にして得られたPQQフリー体30mgを66℃、30分間でメタノール蒸気8.5gに接触させて、赤色の固体のPQQフリー体を黄色の固体に変化させた。該黄色の固体(PQQメタノール付加物)は33mg得られた。これよりガス状のアルコールを使用しても、PQQフリー体とアルコールとの反応は進行することが分かった。
実施例1で得られたPQQメタノール付加物にリン酸バッファー(インビトロジェン製 pH7.4)に加えて、1mg/MLのPQQメタノール付加物溶液を得た。該PQQメタノール付加物溶液を室温で2時間放置後、高速液体クロマトグラフィー分析した。当該分析により、該PQQメタノール付加物溶液中には、PQQが0.92mg/ML存在していることが分かった。すなわち、実施例1で得られたPQQメタノール付加物は、リン酸バッファーを加えて室温で2時間放置することにより、元のPQQフリー体に戻っていた。
実施例1と同様にして得られたPQQフリー体1.98gをエタノール40gと混合し、65℃で6時間反応させて黄色の固体を析出させた。析出させた黄色の固体を、遠心分離し、エタノール洗浄した後、減圧乾燥して1.95gの淡黄色の固体(PQQエタノール付加物)を単離した。
実施例1と同様にして得られたPQQフリー体380mgをメトキシエタノール15gと混合し、60℃で16時間反応させた後、室温で3日放置すると黄色の固体が析出した。析出した黄色の固体を、遠心分離し、ジエチルエーテル洗浄した後、減圧乾燥して0.28gの黄色の固体(PQQメトキシエタノール付加物)を単離した。
実施例2及び5で得られたPQQメタノール付加物及びPQQエタノール付加物を以下のとおり分析した。
実施例2で得られたPQQメタノール付加物を重メタノール中で1H-NMR、13C-NMR、HMBC及びHMQCの2次元測定をおこなった。
PQQフリー体の1H-NMR及び13C-NMRを重ジメチルスルホキシド(重DMSO)溶媒中で測定した。なお、当該実施例において、PQQフリー体は、実施例1と同様の方法で得られたPQQフリー体とした。
実施例2で得られたPQQメタノール付加物のIRの結果、実施例5で得られたPQQエタノール付加物のIRの結果、PQQフリー体のIRの結果を、順に図1~3に示す。
PQQフリー体10mgを下記各溶媒10mLに加えて生成物を得た。さらに該生成物を下記所定の溶媒で100倍希釈してUVスペクトルを測定した。
比較例1:水100質量%
参考例1:水90質量%+メタノール10質量%
実施例8-1:水40質量%+メタノール60質量%
実施例8-2:水10質量%+メタノール90質量%
実施例8-3:メタノール100質量%
表1に示すとおりPQQフリー体10mgと各種アルコール5mLとを混合し、65℃で加熱して反応させた。当該反応において、PQQフリー体が各種アルコールに溶解する時間と色の変化とを観察した。結果を表1に示す。
大腸菌JM109株を30℃LB培地で一晩培養した。該培養した大腸菌JM109株を、GIBCO製pH7.4のリン酸バッファー(PBS)で希釈して660nmの濁度0.57の溶液1とした。該溶液1を表2に示す各サンプル8mgに100μL加えて、室温で30分後、さらにPBSを900μL加えて溶液2を得た。該溶液2をLB寒天培地のシャーレに植え、30℃で培養することで生菌数を溶液2中のコロニーの数より求めた。
表3に示すとおり、PQQジナトリウム水溶液 0.2M 1mLに2N塩酸を所定量加えて、ホットプレート上で乾燥した後、エタノール10mLと50℃で1時間反応させて色の変化を観察した。
PQQフリー体0.86gを2-プロパノール80gと混合し、加熱還流しながら、24時間反応させた。得られた反応液からエバポレーターでイソプロパノールを除去し、黄色の固体(PQQ2-プロパノール付加物)1.06gを得た。
PQQジナトリウム10mgをメタノール10mLに加えて懸濁液を作った。この懸濁液をメタノールで20倍に希釈した溶液(100%メタノール溶液)を作製した。当該溶液についてUVスペクトルを測定した。結果を図9に示す。
PQQジナトリウム10mgをメタノール10mLに加えて懸濁液を作った。この懸濁液を水で20倍に希釈した溶液(5%メタノール溶液)を作製した。当該溶液についてUVスペクトルを測定した。結果を図10に示す。
PQQフリー体10mgを下記各溶媒10mLに加えて生成物を得た。さらに該生成物を下記所定の溶媒で100倍希釈してUVスペクトルを測定した。
比較例7:水100質量%
参考例4:水90質量%+エタノール10質量%
実施例27-1:水40質量%+エタノール60質量%
実施例27-2:水10質量%+エタノール90質量%
実施例27-3:エタノール100質量%
表5に示すとおり各サンプル5mgを0.25mLのポリプロピレン製容器に入れ、オーブンに入れて各温度における変化を0.5、3及び24時間後並びに7日後に観察した。なお、食用油脂としては、日清オイリオODO100μLを使用した。
Claims (10)
- 請求項1に記載の化合物又はその塩を含む組成物。
- コエンザイムQ10をさらに含む請求項2に記載の組成物。
- 請求項1に記載の化合物若しくはその塩、又は請求項2若しくは3に記載の組成物を用いた飲料。
- 請求項1に記載の化合物若しくはその塩、又は請求項2若しくは3に記載の組成物を用いた食品。
- 請求項1に記載の化合物若しくはその塩、又は請求項2若しくは3に記載の組成物を用いた化粧品。
- 粉末、錠剤、チュアブル錠、カプセル、顆粒、注射剤、液剤、点眼剤、ローション剤、ヘヤートニック、化粧用乳液、スプレー液、エアロゾル、ドリンク液、液体肥料又は保存用溶液の形態である請求項2又は3に記載の組成物。
- 前記工程が水分量50質量%以下の溶媒中で行われる請求項8に記載の製造方法。
- 前記ピロロキノリンキノンの塩がモノアルカリ金属塩である請求項8又は9に記載の製造方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/349,228 US9604979B2 (en) | 2011-10-03 | 2012-09-24 | Pyrroloquinoline quinone alcohol adduct |
CN201280048910.6A CN103857676B (zh) | 2011-10-03 | 2012-09-24 | 吡咯喹啉醌醇加成物 |
JP2013537468A JP6056762B2 (ja) | 2011-10-03 | 2012-09-24 | ピロロキノリンキノンアルコール付加物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011218968 | 2011-10-03 | ||
JP2011-218968 | 2011-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013051414A1 true WO2013051414A1 (ja) | 2013-04-11 |
Family
ID=48043576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/074411 WO2013051414A1 (ja) | 2011-10-03 | 2012-09-24 | ピロロキノリンキノンアルコール付加物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9604979B2 (ja) |
JP (1) | JP6056762B2 (ja) |
CN (1) | CN103857676B (ja) |
WO (1) | WO2013051414A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107207494A (zh) * | 2015-01-19 | 2017-09-26 | 三菱瓦斯化学株式会社 | 溶解性高的丙酮加成吡咯喹啉醌盐 |
JPWO2018003531A1 (ja) * | 2016-06-29 | 2019-04-18 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 |
JP7449469B2 (ja) | 2020-04-01 | 2024-03-14 | 三菱瓦斯化学株式会社 | 結晶及びその製造方法、組成物、ソフトカプセル |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2019082550A1 (ja) * | 2017-10-25 | 2020-11-12 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン含有グミキャンディ及びその製造方法 |
US20190298684A1 (en) * | 2018-03-27 | 2019-10-03 | So Young Life Sciences Corporation | Compositions For Reducing Negative Effects Of Alcohol Consumption |
US11452715B2 (en) | 2018-04-13 | 2022-09-27 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
US11453664B2 (en) | 2018-04-13 | 2022-09-27 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
US11453665B2 (en) | 2018-04-13 | 2022-09-27 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
EP3845074A4 (en) * | 2018-08-30 | 2021-10-27 | Mitsubishi Gas Chemical Company, Inc. | PHOTODEGRADATION INHIBITOR, DRINK WITH IT AND PROCESS FOR INHIBITING PHOTODEGRADATION |
US11419849B1 (en) | 2019-02-06 | 2022-08-23 | Kitt Bio, Inc. | Methods and products for adverse effects of air travel, jet lag, or a change to a sleep wake timing cycle |
US11358963B2 (en) * | 2020-03-05 | 2022-06-14 | Ankh Life Sciences Limited | Low-temperature synthesis of thymoquinone and harmaline compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0570459A (ja) * | 1991-09-12 | 1993-03-23 | Yoshiki Oshiro | 新規なピロロキノリン化合物 |
US20110152526A1 (en) * | 2009-12-23 | 2011-06-23 | Berry And Associates, Inc. | Methoxatin derivatives |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10345097A1 (de) * | 2003-09-26 | 2005-04-21 | Basf Ag | Verfahren zur Herstellung von Leder und Halbfabrikaten und dafür geeignete Formulierungen |
JP2011024476A (ja) * | 2009-07-24 | 2011-02-10 | Mitsubishi Gas Chemical Co Inc | ピロロキノリンキノン含有アルコール |
JP2011148755A (ja) * | 2010-01-25 | 2011-08-04 | Mitsubishi Gas Chemical Co Inc | 安定性の高いピロロキノリンキノンとシクロデキストリンで包接された酸化型コエンザイムq10を共に含む経口摂取用組成物 |
-
2012
- 2012-09-24 US US14/349,228 patent/US9604979B2/en active Active
- 2012-09-24 WO PCT/JP2012/074411 patent/WO2013051414A1/ja active Application Filing
- 2012-09-24 CN CN201280048910.6A patent/CN103857676B/zh active Active
- 2012-09-24 JP JP2013537468A patent/JP6056762B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0570459A (ja) * | 1991-09-12 | 1993-03-23 | Yoshiki Oshiro | 新規なピロロキノリン化合物 |
US20110152526A1 (en) * | 2009-12-23 | 2011-06-23 | Berry And Associates, Inc. | Methoxatin derivatives |
Non-Patent Citations (6)
Title |
---|
ANDRES, J. ET AL.: "Quantum chemical studies of pyrroloquinoline quinone: PM3 pathways for methanol oxidation", BIOORGANIC CHEMISTRY, vol. 22, no. 1, March 1994 (1994-03-01), pages 58 - 71, XP024023093, DOI: doi:10.1006/bioo.1994.1005 * |
DEKKER, ROBERT H. ET AL.: "Covalent addition of water, enzyme substrates and activators to pyrrolo-quinoline quinone, the coenzyme of quinoproteins", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 125, no. 1, 1982, pages 69 - 73, XP055211857 * |
ITOH, SHINOBU ET AL.: "C-4 and C-5 adducts of cofactor PQQ (pyrroloquinolinequinone). Model studies directed toward the action of quinoprotein methanol dehydrogenase", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 115, no. 22, 1993, pages 9960 - 7, XP002625971 * |
JOHANNES FRANK JZN ET AL.: "Kinetic and spectral studies on the redox forms of methanol dehydrogenase from Hyphomicrobium X", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 174, no. 2, June 1988 (1988-06-01), pages 331 - 338 * |
PIRRUNG, MICHAEL C.: "Modeling of the chemistry of quinoprotein methanol dehydrogenase. Oxidation of methanol by calcium complex of coenzyme PQQ via addition-elimination mechanism", CHEMTRACTS, vol. 10, no. 11, October 1997 (1997-10-01), pages 828 - 830 * |
SAITO, SHIZUKA ET AL.: "Quinone hemiacetal formation from protocatechuic acid during the DPPH radical scavenging reaction", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 67, no. 7, 8 August 2003 (2003-08-08), pages 1578 - 1579 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107207494A (zh) * | 2015-01-19 | 2017-09-26 | 三菱瓦斯化学株式会社 | 溶解性高的丙酮加成吡咯喹啉醌盐 |
US10131661B2 (en) * | 2015-01-19 | 2018-11-20 | Mitsubishi Gas Chemical Company, Inc. | High-solubility acetone-added pyrroloquinoline quinone salt |
JPWO2018003531A1 (ja) * | 2016-06-29 | 2019-04-18 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 |
US11021476B2 (en) | 2016-06-29 | 2021-06-01 | Mitsubishi Gas Chemical Company, Inc. | Pyrroloquinoline quinone monosodium and method for producing the same, and composition comprising the same |
JP7335070B2 (ja) | 2016-06-29 | 2023-08-29 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 |
JP7449469B2 (ja) | 2020-04-01 | 2024-03-14 | 三菱瓦斯化学株式会社 | 結晶及びその製造方法、組成物、ソフトカプセル |
Also Published As
Publication number | Publication date |
---|---|
JP6056762B2 (ja) | 2017-01-11 |
JPWO2013051414A1 (ja) | 2015-03-30 |
US9604979B2 (en) | 2017-03-28 |
CN103857676B (zh) | 2016-06-08 |
CN103857676A (zh) | 2014-06-11 |
US20150037308A1 (en) | 2015-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6056762B2 (ja) | ピロロキノリンキノンアルコール付加物 | |
ES2717941T3 (es) | Compuestos útiles como moduladores de TRPM8 | |
US9174983B2 (en) | Pyrroloquinoline quinone disodium salt crystal and method for producing the same | |
JPS6013780A (ja) | 茶カテキン類の製造方法 | |
KR100539495B1 (ko) | 글리코실-엘-아스코르브산의아실화유도체 | |
JP6299984B2 (ja) | 黄色系還元型ピロロキノリンキノン結晶及びその製造方法、並びに、食品、医薬品、ゲル、組成物及び組成物の製造方法 | |
JPH06312924A (ja) | 抗酸化作用を有するフムロン類の利用 | |
JP6021166B2 (ja) | 血圧降下剤 | |
WO2013015519A1 (ko) | 비타민나무 잎으로부터 분리한 이소람네틴-3-글루코시드-7-람노시드를 유효성분으로 함유하는 항산화용 조성물 | |
CN106170488B (zh) | 用于取代的1-苄基-3-(1-(异噁唑-4-基甲基)-1h-吡唑-4-基)咪唑烷-2,4-二酮的合成的改进方法 | |
JP6443804B2 (ja) | ナチュラルキラー細胞活性促進剤 | |
JP5122147B2 (ja) | 抗酸化作用を有する2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド | |
JP4537024B2 (ja) | 炎症疾患予防・治療剤 | |
KR102283946B1 (ko) | 유자 유래 항염증 화합물 및 이의 분리방법 | |
KR101123609B1 (ko) | 테트라히드록시 신남메이트 및 테트라히드록시 아마이드 유도체, 이의 제조방법 및 이를 포함하는 미백용 피부 외용제 조성물 | |
JP5122148B2 (ja) | 抗酸化作用を有する2−アシルフロログルシノール−4,6−ジ−C−β−D−グルコピラノシド | |
JP2007051103A (ja) | 抗酸化組成物 | |
JP2007099671A (ja) | 抗酸化組成物 | |
KR102557702B1 (ko) | 아로니아 식초를 포함하는 항염증용 조성물 | |
JP2013053116A (ja) | 還元型pqqの安定化方法 | |
JP2013060397A (ja) | プロトイソフラボン類の製造方法 | |
JP3525267B2 (ja) | 抗酸化作用を有するマロフェノンの利用およびその製造方法 | |
KR101931442B1 (ko) | 항산화 또는 항염증 활성을 나타내는 신규 화합물 | |
KR100641968B1 (ko) | 생리활성 추출물 | |
KR20170091242A (ko) | 많첩빈도리 추출물을 함유하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12838548 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013537468 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14349228 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12838548 Country of ref document: EP Kind code of ref document: A1 |